Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

CONCLUSION: Despite strong evidence of disease control with maintenance therapy, OS remains unaffected and FOCUS4-N provides additional evidence to support the use of treatment breaks as safe management alternatives for patients who are stable or responding to first-line treatment for mCRC. Capecitabine without bevacizumab may be used to extend PFS in the interval after 16 weeks of first-line therapy.PMID:34516759 | DOI:10.1200/JCO.21.01436

Source: Clinical Colorectal Cancer - September 13, 2021 Category: Cancer & Oncology Authors: Richard A Adams David J Fisher Janet Graham Jenny F Seligmann Matthew Seymour Richard Kaplan Emma Yates Mahesh Parmar Susan D Richman Philip Quirke Rachel Butler Ewan Brown Fiona Collinson Stephen Falk Harpreet Wasan Kai-Keen Shiu Gary Middleton Leslie Sa Source Type: research